Chanelle's head of sales and marketing, Killian Gaffney said: "The total UK market is around 80,000 bottles annually. However, with the major supplier announcing some re-stocking in March but full availability still under question, there is a real sense of urgency for practitioners.
"The Chanelle team worked throughout December with our manufacturing division to ensure that the UK product shortfall could be alleviated.
"Air freighting supplies seemed the obvious course of action, and ensured we could supply the UK market as quickly as possible."
For further information, contact: Chanelle on 00353 91 841 788.
Henry Schein said in a statement on Friday that it had sold the business in order to focus on its dental and medical markets and pursue new investment opportunities.
Covetrus says it will be using the experience, technology and global scale of the merged companies to provide veterinary practices with a more comprehensive set of integrated services and technology solutions, and tools to strengthen client relationships and grow their practice.
Covetrus launched on Nasdaq last Friday, when President and Chief Executive Officer Benjamin Shaw, said: "Today marks an important new chapter in the world of veterinary medicine, as we launch Covetrus as a new company listed on Nasdaq.
"We look forward to strengthening our customer relationships and expanding our veterinary practice partnerships worldwide as we bring more comprehensive and powerful solutions to market to meet their evolving needs and improve health and financial outcomes."
The company says that so far, it has had no cases of flu reported in horses vaccinated with Equip F or Equip FT in the UK. However, it cautions that in the present flu outbreak it is not clear if any of the current influenza vaccines will provide complete clinical protection against the mutated strain.
In addition, Zoetis highlights that:
Equip F and Equip FT are both indicated for reduction in clinical signs caused by Equine Influenza, including Florida Clade 1 strains.
Cross protection has been demonstrated by virulent challenge for representative strains of Florida Clade 1 (Paillot et al 20081, Bryant et al 20102) and Clade 2 (Paillot et al 20153).
Vaccination with Equip F stimulated a flu specific cell-mediated immune response to a Clade 1 strain which was detectable for up to one year after the third vaccination in primary course (Paillot et al 20153).
Zoetis says it is confident that the Equip range continues to be effective against its licensed indications.
If you have further questions about the vaccines, ring 0845 300 8034 and choose option 1 to speak to Zoetis' technical team.
References
Supplies of the vaccine, which is indicated for the active immunisation for horses against equine arteritis, ran low at the end of last year when Zoetis' existing stock was due to expire without any new stock in place.
For further information, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 choosing option 1.
Sarah Gasper, BEVA’S Learning Manager said: "Many of us on the BEVA education team understand exactly what it’s like to return to practice whether after a career break, paternity/maternity or sickness leave. We also understand the specific challenges of moving from mixed into equine practice.
"We have created these courses to help make the transition back to work as smooth as possible. We’ve tried to incorporate everything we wish we had had access to when we returned to practice!"
Reinvigorate your approach to equine practice will be held on 12th March 2019 at Lythe Hill Hotel, Haslemere. The lecture and forum based course will explore the latest advances in internal medicine, orthopaedics, and sports medicine, and how to apply them to develop evidence-based clinical approaches to common and emergency scenarios in practice.
Getting (back) into equine practice will be held on 13th March 2019 at Liphook Equine Hospital, Hampshire. This entirely practical day of CPD will all be about improving the confidence of established equine vets and for vets returning to work following a career break. The course will focus on the practical procedures that an established equine ambulatory vet might be expected to perform on a regular basis. In a new approach to CPD we are trialling a system where delegates can shape part of this unique CPD day for themselves, with an online poll pre-course to select from a choice of practicals.
Both courses will have childcare facilities to help support parents wishing to attend CPD.
BEVA will also be running a course on the fundamentals of sedation, field anaesthesia and castration on 27th and 28th March 2019 at World Horse Welfare, Snetterton, Norfolk. This 'hands-on' course is designed for new or recent graduates or those in mixed practice with varied levels of equine work. It comprises evening lectures on the first day to free up more time for hands-on training on day two. It will cover sedation and field anaesthesia required for common field surgery such as castration, both in theory and in a practical session, with the equine welfare charity venue able to provide a high number of colts for castration work. Nerve blocks and regional anaesthesia for other common procedures will also be covered on cadavers.
For further information on BEVA’s new CPD courses visit www.beva.org.uk/cpd
The company says the new product has been launched in response to demand from UK equine veterinary surgeons specialising in dentistry
Hexarinse for Horses is presented as a palatable, mint-flavoured, ready-to-use formulation in a five litre container.
Virbac says the antibacterial action of chlorhexidine supports the maintenance of oral health after dental procedures and may aid the management of periodontal disease, oral inflammation and the management of peripheral caries.
For further information, speak to your local Virbac territory manager or contact Virbac Limited on: 01359 243243 or enquiries@virbac.co.uk.
Their study, which was published in the research journal PeerJ at the end of last year1, investigated the effects of insulin on equine hoof lamellar cells in the laboratory.
The researchers say that high levels of insulin have been known for some time to cause acute endocrine laminitis, seen when ponies and certain types of horses graze lush pasture or consume a starch- or sugar-rich diet, or when they develop Cushing’s syndrome.
Many ponies and horses at risk of the condition produce large spikes of insulin in their blood stream after consuming meals high in non-structural carbohydrates (in particular starch and simple sugars) which indicates that this could be the way in which they succumb to acute endocrine laminitis.
The mechanism by which insulin can cause effects in the foot leading to laminitis has been the subject of much debate in recent years.
Hormones like insulin must interact with a specific receptor on the surface of cells in order to produce their effects. What has confused researchers in the past is that there appear to be no insulin receptors on the hoof lamellar cells (these cells give the lamellar tissues their strength and changes to their growth or structure weaken the bonds and cause laminitis).
The researchers considered the close similarities between insulin and a growth factor hormone called insulin-like growth factor -1 (IGF-1). There are receptors for IGF-1 on the lamellar cells, and the researchers speculated that high concentrations of insulin might be able to cross-stimulate these cells by activating the IGF-1 receptors. To investigate this possibility PhD student Courtnay Baskerville, together with her supervisor Professor Simon Bailey, developed a method for culturing lamellar epithelial cells in the laboratory, and incubated them with increasing concentrations of insulin.
They found that high concentrations of insulin stimulated the cells to proliferate. Furthermore, this effect could be prevented using an antibody that specifically blocks only the IGF-1 receptor. Further downstream effects within the cells were also shown. The changes seemed to occur mainly at very high concentrations of insulin. Similar concentration levels can be seen in ponies and horses with insulin dysregulation linked to Equine Metabolic Syndrome, but are not commonly seen in normal horses that are considered to be at lower risk of laminitis.
Further work is now ongoing to determine exactly how these cellular changes induced by sustained high insulin concentrations might cause laminitis. However, it seems that targeting the IGF-1 receptor may be an option for developing new drugs to prevent and treat laminitis.
Professor Simon Bailey said: "The information gathered in this study provides the equine industry worldwide with valuable insights into the causes of the common and serious condition of laminitis. The research group would like to acknowledge the support of the Waltham Centre for Pet Nutrition, in particular the involvement of Professor Pat Harris.”
Reference
In its statement, the company blamed the situation on the poor performance of 24 practices it bought in the Netherlands, and its new farm and equine divisions.
CVS says that another important factor has been employment costs, in particular the increase in market rates for locum veterinary surgeons and nurses on which it remains heavily reliant.
The company also blames its financial performance on the poor support of pharmaceutical companies, which it says it is continuing to push for transparent and 'appropriate' pricing.
Aside from trying to drive down the costs of drugs, the company says it has introduced 'additional procedures' designed to reduce the cost of employing locums, although it didn't specify what these are.
The group is also reevaluating its pipeline of acquisitions, in particular the multiples it is prepared to pay.
At the time of writing, the CVS share price had dropped over 28% to 465p overnight and 70% since the share price peaked at 1477p in November 2017.
In the game of acquisitions musical chairs, did the music just stop?
Full trading statement.
At the June 2017 meeting of RCVS Council, members decided to look into two models by which paraprofessionals working in the veterinary, animal health or related fields, might be regulated by the College under powers granted by the RCVS’s Royal Charter in 2015.
The first was an accreditation model, which would involve the RCVS accrediting an organisation which would regulate the profession in question. The second was an associate/ full regulation model, in which individual paraprofessionals would receive a similar level of regulation to that already received by veterinary surgeons and veterinary nurses.
At its January 2019 meeting, RCVS Council agreed to proceed with both proposed models of paraprofessional regulation, with the suitability of each model being considered on a case-by-case basis, depending on the nature of the profession applying for recognition.
Paraprofessions whose work will need to be underpinned by Schedule 3 reform would need to apply for the associate model, as the RCVS would be required to be directly responsible for the register of any individuals undertaking such minor acts of veterinary surgery.
Two paraprofessional groups that have already expressed an interest in being regulated by the College, namely meat inspectors and animal behaviourists, will now be invited to apply for associate or accredited status.
Eleanor Ferguson, RCVS Registrar, said: "This is a very significant decision by Council to open up a pathway to related paraprofessions to apply to become regulated by the College.
"It is difficult to give a time-frame at this stage as to when these particular professions will be brought on board, as we will have to go through a process of developing a number of new regulatory structures including registration, education and investigation and disciplinary, as well as the appropriate governing bodies for each of the professions.
"However, we are very pleased that the Association of Meat Inspectors (AMI) and the Animal Behaviour and Training Council (ABTC) have expressed an interested in being regulated by the College and we look forward to working with them to make this happen."
David Montgomery, President of the ABTC, said: "The ABTC enthusiastically welcomes the news that the RCVS is expanding its influence to include paraprofessionals. We look forward to exploring the opportunity to demonstrate the professional status of ABTC-registered Animal Trainers and Behaviourists by coming under the regulatory umbrella of the RCVS for the benefit of animal welfare."
Ian Robinson, a Trustee of the AMI, said: "The Association of Meat Inspectors welcome the news that the Royal College of Veterinary Surgeons intends to invite paraprofessionals to be regulated under the ambit of the RCVS. We believe it will offer enhanced security, opportunity and status, and we look forward to further dialogue to explore the various models in due course."
The College says it is also in touch with a number of other paraprofessional groups, including those representing animal musculoskeletal practitioners and equine dental technicians, about the future of paraprofessional regulation. However, before such professions could become associates, there would need to be reform of the Veterinary Surgeons Act in order to remedy some of the deficiencies of the current legislative regime and make sure that these groups have appropriate legal underpinning for their work. This, says the College, complements ongoing discussions on changes to the legislative framework to bolster the role of veterinary nurses.
On particular issue that the College says the new proposals are designed to remedy is that of equine dental procedures being carried out by well-trained but nevertheless unregulated paraprofessionals. Neil Townsend, Chair of the British Equine Veterinary Association’s (BEVA) Allied Professional Committee, said: "Change to the current situation, where legislative enforcement is impossible, horse owners are confused, and horse welfare is compromised, is long overdue. BEVA is really pleased that the RCVS has listened and is supporting a proposal for regulation of all equine dental procedures. We hope that Government will act."
RCVS President Amanda Boag, said: "This is a real milestone in the history of the RCVS and represents quite possibly the biggest change to our regulatory role since the introduction of the Register of veterinary nurses in 2007, and should Schedule 3 reform be achieved it would be the most significant change since the role of veterinary nurses was first recognised in law in 1991. It is particularly befitting for our 175th anniversary year, as it demonstrates we are an organisation that can evolve to meet the changes occurring in the wider veterinary and animal health sector and use our regulatory experience and expertise to ensure that animal health and welfare and public health is safeguarded in different, but related fields of endeavour."
The full approved paper regarding the review of the minor procedures regime and paraprofessional regulation can be found on the RCVS website at: https://www.rcvs.org.uk/news-and-views/policy/veterinary-legislation-review/
Andrea Tarr BPharm MSC MRPharmS, the founder and director of Veterinary Prescriber said: "Prescribing is a neglected aspect of veterinary practice. When it comes to making treatment decisions, vets are very poorly supported by their professional organisations, the pharmaceutical industry has a hugely distorting influence and there's a lack of access to really helpful information.
"We're determined to use the expertise in Veterinary Prescriber to change this, and support vets in their use of medicines in the best interests of animals, their owners and the environment.
"With this in mind, we start the year with a learning module of good veterinary dispensing practice."
The module explains what constitutes a well-run dispensary, including how to organise, handle and store medicines correctly. It reviews the legal classifications of medicines, including controlled drugs and the cascade. It also considers why dispensing errors occur and what to do when they happen.
Veterinary Prescriber says its modules are evidence-based, peer-reviewed and independent of the pharmaceutical industry.
Subscription costs £9.95 per month, which you can cancel any time. To subscribe, visit: www.veterinaryprescriber.org
A free copy of the compendium has been sent to every veterinary practice in the UK, and it is also available online at: www.noahcompendium.co.uk. A special edition of the book commissioned by AMTRA will also be available for its SQPs shortly.
NOAH chief executive Dawn Howard said: "The NOAH Compendium, in all its formats, remains a major part of NOAH’s efforts to ensure appropriate access and responsible use of medicines for all animals. We are pleased it is even more comprehensive this year, as we continue to expand its list of contributors.
"Every NOAH member, as well as the non-member participants in the NOAH Compendium, is a signatory to the NOAH Code of Practice on Promotion, which demonstrates their commitment to operate above and beyond any regulatory requirements."
She added: “As well as product datasheets, the Compendium includes another vital resource – the contact details for each participating company. Company veterinary and technical advisors have detailed knowledge about their company’s medicines. The NOAH Code includes the requirement for NCAH qualification for NOAH staff in technical dialogue with prescribers and users of animal medicines – meaning their advice can be regarded as a valuable and trusted resource. They are ready to talk to prescribers about the use of a medicine in a particular animal or in a particular situation, as well as to explain any queries about the data sheet."
Veterinary practices that have not yet received a copy, perhaps because they are new or have changed address in the past year should contact NOAH (noah@noah.co.uk).
Extra copies are also available to order, for £47.50. Special prices are also available for bulk orders.
Having investigated alternative sources of isoflurane, and alternative products, the associations proposed ways that the VMD might mitigate the risks to animal welfare including consenting to the use of unlicensed (“special”) isoflurane formulations.
The VMD responded rapidly and positively. It is understood that one specials manufacturer is now intending to produce isoflurane to fill or partially fill the gap in supply. This should be available in three to four weeks.
David Rendle, a member of BEVA’s Health and Medicines Committee commented: "BEVA has a close relationship with the veterinary pharmaceutical industry and will always work swiftly and collaboratively to help develop practical solutions to supply problems for our members."
BSAVA President Philip Lhermette praised the VMD for such prompt action. He said: "The VMD listened to our concerns and acted immediately. By doing so they have addressed and helped to prevent any potential welfare risks associated with a lack of isoflurane."
Carl Bradbrook, AVA Junior Vice President, reminded clinicians to "seek advice when considering the use of unfamiliar anaesthetic protocols."
The associations say that the situation doesn’t give vets free rein to ignore the medicines legislation; the cascade must still be followed, and client informed consent obtained if an unregulated anaesthetic is used.
Extemporaneous products are the last tier of the cascade. Vets are expected to use either an authorised human medicine or an EU authorised veterinary medicine before an extemporaneous preparation. If, after diligent attempts to source a product higher up the cascade, the vet has not been successful they could consider using an extemporaneous preparation for the immediate need. However, should an authorised product or a human product become available vets are obliged to use it over an extemporaneous preparation.
BEVA, the BSAVA and the AVA have each produced general advice on the use of specials or anaesthesia options at https://www.bsava.com/News/ArticleID/2535/Isoflurane-supply, https://www.beva.org.uk/Resources-For-Vets-Practices/Medicines-Guidance/Veterinary-specials and https://ava.eu.com/
Equip Artervac is indicated for the active immunisation for horses against equine arteritis virus to reduce the clinical signs and shedding of virus in nasal secretions following infection.
Zoetis says it is working hard to resolve the situation and apologises for any convenience caused.
For more information, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 choosing option 1.
The webinar, which is presented by equine internal medicine specialist David Rendle from Rainbow Equine Hospital, challenges some of the current perceptions of worm control in horses and explains why veterinary surgeons need to engage more with horse owners on the topic to ensure a sustainable approach to parasite control.
Supported by Virbac, maker of Equimax and Eraquell horse wormers, the webinar is free to BEVA members at http://www.ebeva.org/webinar74.
There are three awards on offer: two ruminant bursaries and one companion animal bursary. Applications must be in by 30th November 2018.
Each project should be completed within one to two years and the vet practitioner proposals will be judged by university academics to ensure independent assessment.
The companion animal research bursary will be assessed by the University of Nottingham Centre for Evidence-based Veterinary Medicine and the ruminant research bursary applications will be assessed by academic staff from the University of Bristol School of Veterinary Science.
Michelle Townley, veterinary advisor at MSD Animal Health (pictured right) said: "New knowledge and good research skills form the lifeblood of the industry so we’re keen to get as many applications as possible as part of our commitment to encouraging research in the veterinary industry."
For further details go to the MSD Animal Health Research Bursary website: www.msdahresearchbursary.co.uk.
Virtual Vet Derms has been set up to be able to give advice to veterinary surgeons on any aspect of skin or ear disease whether it is allergy, otitis media, cutaneous neoplasia or endocrine-based in any species, including dogs, cats, small furries, exotic pets including raptors, birds and reptiles, horses, camelids, zoo and farm animals.
Sue, herself an RCVS Recognised Specialist in Veterinary Dermatology, is supported by a team of veterinary dermatology colleagues as well as veterinary specialists in exotic medicine, internal medicine (including endocrinology) and consultants with expertise in oncology.
Sue said: "We recognise that not every veterinarian has got access to a local dermatology specialist and that not all clients can or want to travel to a referral centre. The aim of the service is to formalise the advice that dermatology clinicians give to veterinary surgeons to allow them to get detailed help to manage difficult or challenging dermatology cases within their own practice."
The service has been set up under the RCVS Vivet initiative, is approved by all of the major insurance companies and supported with Veterinary Defence Society Insurance cover.
Virtual Vet Derms offers support in a range of ways.
Quick questionsShort questions that veterinary surgeons can submit via the online form on the Virtual Vet Derms website that just require a brief reply. This may be a dose of a drug, a parasite you want identifying, or the interpretation of a blood sample such as an ACTH stimulation test.
Veterinary reportsVeterinary surgeons can use online request forms on the Virtual Vet Derms web site to submit a brief history of the animal and the problem and some good quality photos of the skin condition. There is also the ability to upload histopathology reports, blood samples and any other pertinent information. A detailed written report is sent back to the vet within 48 hours which will describe clinical signs, differential diagnoses, recommended diagnostic tests and treatment option where appropriate. Where possible, Virtual Vet Derms aims to pass the advice request to the nearest dermatologist but vets can ask for advice from any of its specialists.
Telemedicine consultationsFor new cases or for cases where initial advice has been sought, in the client's own primary care veterinary practice via the internet. The Virtual Vets Derms specialist can consult with the owner to provide even more specific advice and support. After each teleconsultation the Virtual Vet Derms specialist will produce a report in the same format as the veterinary report to allow the primary care veterinary surgeon to continue to manage the case more effectively.
Face to face consultationsCan also be arranged via the owner’s vet at the specialist's own practice if there is the need for more specialist investigation that may not be available in the primary care veterinary surgery. In these cases, the specialist will take on the direct care of the case and work with the owner and vet on the best course of action.
General advice Also possible if the vet wishes to direct an owner straight to Virtual Vet Derms.
For more information, visit: https://virtualvetderms.com
The range includes:
Fluodrop (the first fluorescein product specifically designed for veterinary use)
Ocryl - an ocular and periocular cleanser that can also be used to reduce and prevent unsightly tear staining
Ocular lubricants (carbomer and hyaluronic acid based)
Clerapliq – a novel molecule to the UK veterinary market that is used to help restore and regenerate the corneal extracellular matrix
The products will be supported with a selection of materials to help vets, nurses and pet owners in the maintenance of corneal health, including diagnosis and treatment guidelines, anatomical guides, posters and client educational and treatment aids to help with compliance.
William Peel MRCVS, product manager at TVM-UK said: "Our Corneal Focus Range is an exciting way to expand on our product portfolio following the successful introduction of our ‘Anti-tox’ range.
"With ‘Anti-tox’ we successfully managed to make vets and nurses lives easier by providing education and materials alongside a great range of products to help when dealing with poisoning cases in practice. We also attempted to make clients more aware of the dangers of poisoning in pets.
"We hope to emulate this approach and success with our Corneal Focus Range – by developing a wealth of materials for vets, nurses and clients to aid them in managing and understanding ophthalmology cases – and by providing quality products."
TVM UK will be showcasing its new products and support services at the London Vet Show (stand P40) this November.
For more information, visit: http://www.tvm-uk.com/
Current World Organisation for Animal Health (OIE) recommendations are to include a representative strain from each of the two sublineages of equine influenza virus (EIV) - Florida Clade 1 and Florida Clade 2, to deliver optimum protection.
MSD's study was designed to evaluate the efficacy of Equilis Prequenza, containing whole virus Newmarket/2/93 (European strain) and South Africa/4/03 (Clade1) EIV strains, and an HA canarypox vectored vaccine containing Florida Clade 1 and Clade 2 strains.
Two groups of seven Fjord ponies were vaccinated twice, 4 weeks apart (V1 on day 0 and V2 on day 28). One group was vaccinated with Equilis Prequenza (MSD AH) and one group with ProteqFlu (Boehringer Ingleheim). The protective antibody response was measured and ponies were challenged, along with six unvaccinated control ponies, by experimental infection with Wexford/14 (a heterologous clade 2 strain), 1 20 days (4.5 months) after V2, and clinical signs and virus shedding monitored. EI serology was measured by single radial haemolysis (SRH) and hemagglutination inhibition (HI). Clinical signs and virus shedding (measured by qRT-PCR and egg titration) were compared between groups and with controls.
Vicki Farr, BVetMed MRCVS, equine veterinary advisor at MSD Animal Health said: "Following challenge at 120 days after V2 with Wexford/14, this study demonstrates that both vaccines provide a highly significant degree of protection against clinical signs of EI and viral shedding compared to unvaccinated controls. Although the study was not designed to compare the efficacy of the two vaccines, because of practical limitations on the number of animals and hence low power, there was no evidence of any significant differences between these two groups. There was, however, a trend towards slightly lower clinical score on days 4-8 and reduced virus excretion on days 2-5 in the Equilis Prequenza group compared to the HA canarypox vectored vaccine.”
MSD says Equilis Prequenza offers a broad based approach to immunogenicity by addressing and adapting key areas of an equine influenza vaccine - Matrix-C adjuvant, whole virus antigen and strain; efficacy has been proven through challenge trials and longer term protection confirmed by serology.
Vicki added: "Equilis Prequenza addresses key factors involved in promoting effective immunogenicity. It combines the demonstrated efficacy against challenge, with a current circulating strain with an established safety profile. Equilis Prequenza stimulates active immunity against EI providing the reassurance your clients demand. MSD Animal Health is committed to working with equine practices to improve vaccination rates in at-risk horses."
For more information about the trial results contact your MSD Animal Health account manager.
The scheme, which is part of the company's Keeping Britain’s Horses Healthy campaign, includes a pack - endorsed by BEVA and World Horse Welfare - to help yard owners and vets educate owners why they should vaccinate and the benefits of preventative healthcare.
The Yard Excellence Scheme pack includes information on vaccination, weight management, worming and biosecurity. It also helps yard owners implement a range of preventative protocols covering things like worming, vaccination and managing new arrivals, and also put infectious disease outbreak protocols in place.
There are also various things to promote the scheme within the yard, such as yard posters, a horse owner checklist, horse records and responsible horse owner booklets.
All the yards that develop and implement appropriate protocols, in collaboration with their vet, will achieve the Keeping Britain’s Horses Healthy Yard Excellence Scheme Standard and will be promoted on the scheme's Facebook page (@keepinghorseshealthy).
Yards can also promote their achievement via social media and on their website.
Fieke Bennett, equine business manager at MSD Animal Health said: "Our KBHH Yard Excellence Scheme is aimed at encouraging yards and vets to collaborate more closely towards excellent preventative healthcare practices.
"By encouraging vaccination and other preventative healthcare practices, livery yards will have a healthier population of horses; achieving an environment with happy horses, happy owners, and excellent yard reputation.
"This collaboration supports a strong relationship between the vet and the yard, a healthy yard means owners can enjoy their love of horses without restriction."
For further information talk to your MSD Animal Health Equine Account Manager, ring 01908 685685 or refer to KBHH social media feeds on Facebook page and Twitter (@keepinghorseshealthy).
Dr Crawford sent the email to his client, Mrs X, on 15 July 2014, the day on which Mrs X’s horse was due for insemination using horse semen supplied from a horse in Germany. However, the semen had arrived without the Intra Trade Certificate, a requirement for intra-EU inseminations, and so Dr Crawford proceeded to contact the Department for the Environment, Food and Rural Affairs (Defra) for alternative authorisation.
Just after 4:30pm on that day, Mrs X received a text from Dr Crawford advising her that he had received authorisation from the AHVLA, and would forward to Mrs X the AHVLA authorisation email. It later transpired that that the email had in fact been fabricated by Dr Crawford using an email that he had previously received from the AHVLA regarding another matter.
Dr Crawford faced the following charges:
Fabricating an e-mail purporting to be from the veterinary officer at the AVHLA, authorising use of semen from a horse for insemination, when in fact he had not received such authorisation.
Dishonesty in relation to the e-mail described above.
His conduct gave rise to spread of infectious disease which had the potential to affect equine animal health and welfare in the region.
Dr Crawford admitted the first two charges, but denied that his actions had given rise to the risk of disease.
The Committee found the first two charges proved, and moved on to determine the facts of the third charge. They took into account that Dr Crawford had received verbal confirmation that the semen was safe, and that the health papers had been stamped accordingly. He had not, however, seen a copy of this certificate and so there was no guarantee that the semen was safe to use at the time he sent the fabricated email. On consideration of the facts, the Committee found this charge proved, as Mrs X’s mare could have been infected and subsequently could have adversely affected equine animal health and welfare in the region.
They also found that his entire course of action had fallen far short of what is expected of a veterinary surgeon, and that it amounted to disgraceful conduct in a professional respect.
When determining sanction, the Committee took into account a number of aggravating factors, namely the risk of injury to animals, an element of pre-meditation, a disregard for the role of the AHVLA, impersonating a fellow veterinary surgeon, and intending to deceive a veterinary surgeon as well as a member of the public.
It did also, however, take into account the mitigating factors – that there was no injury to the animal, and that it was a single isolated incident from which Dr Crawford did not stand to make any financial gain.
The Committee therefore decided to order the Registrar to suspend Dr Crawford’s registration for 12 months.
Ian Green, chairing the Committee and speaking on its behalf, said: "The Committee did consider whether to remove Dr Crawford from the Register. However, in light of the significant mitigation in this case, the fact that this was an isolated incident in an otherwise unblemished career, together with his acceptance from the outset that he had been dishonest and his assurance that he would never behave in this way again, the Committee decided that in all the circumstances to remove him from the Register would be disproportionate."
Dr Crawford can lodge an appeal with the Privy Council within 28 days of being notified of the Disciplinary Committee's decision.
The online seminar, which equates to one hour’s CPD, features six UK experts in equine endocrinology, with the objective of supporting equine and mixed practice vets in using the clinical history to guide their interpretation of the basal ACTH test results and subsequent treatment decisions.
The speakers participating in the Equine Endocrine Pioneers Circle are:
Harry Carslake MA VetMB DipACVIM MRCVS: Senior lecturer in equine medicine at the University of Liverpool
Edd Knowles MA VetMB MVetMed DipECEIM MRCVS: Specialist in Equine internal medicine at Bell Equine Veterinary clinic
Professor Cathy McGowan BVSc DipVetClinStud MACVSc PhD DEIM DipECEIM FHEA MRCVS: Head of Department of Equine Clinical Science and Director of Veterinary Postgraduate Education at the University of Liverpool
Dr Nicola Menzies-Gow MA VetMB PhD DipECEIM Cert EM(Int Med) MRCVS: Reader in equine medicine at the Royal Veterinary College
Victoria South MA VetMB CertAVP(EM) DipECEIM MRCVS: Senior assistant at Liphook Equine Hospital
Nicola Steele BVM&S CertAVP(EM) MRCVS: Fyrnwy Equine Clinic and Director of Veterinary CPD (Equine and Large Animal)
The webinar considers when vets should test for PPID and decision-making on the best test to use, how to interpret grey zone results and also how to interpret problematic follow up tests. The experts have different opinions on some of these areas, allowing vets in practice to see the different ways in which cases can be viewed and managed.
These principles are then reinforced by the use of three clinical case scenarios with the patients all having the same basal ACTH result but a different selection of clinical signs.
Liz Barrett, equine business head at Boehringer Ingelheim said: "Since the launch of our Talk About Laminitis initiative in 2012, more than 50,000 horses have benefited from complimentary basal ACTH tests to aid the diagnosis of PPID, however two common areas of uncertainty in interpreting ACTH results still exist. Firstly, the interpretation of borderline, equivocal or ‘grey-zone’ results and when PPID treatment should or shouldn’t be recommended and secondly, the interpretation of follow-up ACTH test results and when to advise altering the treatment dose.
"The Equine Endocrine Pioneers Circle webinar allows vets to update their knowledge on this broad subject area and illustrates that there is often more than one way to approach the diagnosis, treatment and management of the PPID case."
To view the Equine Endocrine Pioneers Circle webinar on the Boehringer Academy visit https://www.boehringer-academy.co.uk/webinar/bil205
Dr Thomason initially denied both heads of charge, but on the third day of the hearing he changed his plea and admitted the charge in its entirety.
The first part of the charge related to the fact that the seller of the horse was a both a client of Dr Thomason’s practice and a personal friend of his, and he therefore had a potential and/or actual conflict of interest.
Dr Thomason did not disclose this professional and personal relationship to the prospective purchaser before the pre-purchase exam.
The prospective purchaser only discovered Dr Thomason’s relationship with the seller when reading the vetting certificate at home, and stated that, in the past, she had had a similar experience in which the horse was then found to be lame. She later found out the extent of the personal relationship, when invited to join the seller on a social media site.
The Committee found that, in this set of circumstances, Dr Thomason should not have undertaken the pre-purchase exam at all, and, at the very least, disclosed his personal and professional relationship with the vendor.
The Committee also found that although Dr Thomason did have a system in place to inform any prospective purchasers if the vendor was a client of his practice, this failed to work on this occasion and neither the practice nor Dr Thomason told the prospective buyer that the seller was a client before booking the pre-purchase exam. Dr Thomason had no similar system in place to disclose any close friendships with sellers.
Dr Thomason did not consider there was a conflict of interest as he felt confident he could carry out the pre-purchase exam impartially. In addition, it was his belief that the seller had been alerted to the conflict through a system in place at his practice, implemented to safeguard against this type of error. He stated that he in no way attempted to hide his relationship with the seller to the prospective purchaser.
It was not alleged that Dr Thomason had acted dishonestly.
Ultimately, the Committee found Dr Thomason not guilty of disgraceful conduct in a professional respect.
Ian Green, chairing the Committee and speaking on its behalf, said: "Whilst the Committee concluded that the respondent’s view of his obligations to disclose both the professional and personal relationships he had with the vendor was mistaken, it did not find any improper motivation on his part. It has already noted that he sought to disclose to the prospective purchaser through his system the fact that the vendor was a professional client of his.
"The Committee has weighed all these matters very carefully. It is for the client to determine whether or not to proceed with a PPE when in possession of all relevant facts in relation to any potential conflict of interest, and not for the veterinary surgeon to decide. The autonomy of the client must be respected. The Committee was firmly of the opinion that a failure to comply with the Code is very serious. However, taking into account the particulars of this case, the Committee does not consider that the actions of the respondent amount to disgraceful conduct in a professional respect."
EnteroZoo is a dietary supplement composed of organic mineral and purified water in a gel suspension. Enteromed says it works by binding bacterial toxins as it passes through the animal's digestive tract, thereby helping to maintain a healthy gut and intestinal balance.
Enteromed says that compared to old classic adsorbents, such as clay or charcoal, EnteroZoo can be used long-term and is gentle on an animal's intestines.
The company points to a new in-vitro study from Brighton University School of Pharmacy & Biomolecular Sciences which has shown that EnteroZoo adsorbs E. coli, Shigella and C. difficile toxins1 – common causes of gastrointestinal infection and diarrhoea.
EnteroZoo is suitable for all animals including pregnant and nursing females. It is tasteless and odourless and the company says animals generally accept it without any problems. It can be administered in various ways: directly into the mouth, mixed into feed, put on a treat, mixed in an appropriate amount of water or administered with a plastic syringe into the oral cavity.
For more information, contact: enterozoo@enteromed.co.uk, or visit: www.enterozoo.co.uk
Equitop GLME is a palatable, pearl formulation joint supplement developed to support the healthy function of cartilage, joint capsules, tendons and ligaments. It is derived from an active extract of New Zealand Green Lip Mussels - a natural source of glucosaminoglycans (GAGs), chondroitin and essential fatty acids – and is tested free of prohibited substances.
Boehringer says the nutrients in Equitop GLME help to lubricate joints, as well as supporting normal joint function, the stability and elasticity of ligaments and the shock-absorbing properties of cartilage.
Equitop GLME is fed once a day either separately or mixed with feed and one tub will typically last for 30 days and can be used in all horses and ponies.
Dr Amy Scott, brand manager for Equitop GLME at Boehringer Ingelheim, said: "By encompassing Equitop GLME into the Equitop portfolio and launching easy-to-read new packaging, we are enhancing our product offering to both veterinary practices and horse owners."
For more information, contact your Boehringer account manager.